Effects of prostacyclin analogues in in vivo tumor models.
Much attention has recently focused on the role of tumor cell-platelet interaction in the metastatic cascade. Prostacyclin and stable prostacyclin analogues have been shown to inhibit specifically the formation of metastases in experimental tumor models. This action is based on their ability to reduce the attachment of tumor cells to platelets and to inhibit adhesion of tumor cells-platelet aggregates to the endothelial lining. To investigate the antimetastatic potential of two prostacyclin analogues (Iloprost and Eptaloprost, Schering AG), we have tested these compounds in the spontaneously metastasizing R 3327 MAT Lu prostate carcinoma of the Cop rat in two types of experiments. Treatment was performed for 33 days, starting one day before s.c. implantation of the tumor. The primary s.c.-implanted tumor remained in situ throughout the experiment. In the first test, Iloprost (0.3 micrograms/kg/min) and Eptaloprost (0.1 micrograms/kg/min) were administered via Alzet mini pumps s.c.. There was a considerable reduction of the number of visible lung metastases by Eptaloprost. In the second test, Eptaloprost was administered p.o. in doses of 0.1 and 0.5 mg/kg daily. The number of lung metastases was significantly reduced. Both compounds had no effect on the growth of the primary tumor in the first as well as in the second test. These data show that the prostacyclin analogue Eptaloprost has a significant antimetastatic activity in a spontaneously metastasizing tumor model and thus merits further investigation.
Schneider
M R
MR
Research Laboratories of Schering AG Berlin/Bergkamen West Germany.
Schillinger
E
E
Schirner
M
M
Skuballa
W
W
Stürzebecher
S
S
Witt
W
W
D000818:Animals; D000970:Antineoplastic Agents; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016285:Iloprost / Q000031:analogs & derivatives / Q000627:therapeutic use; D015394:Molecular Structure; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000556:secondary; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011355:Prodrugs / Q000627:therapeutic use
D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; C067428:eptaloprost; D011464:Epoprostenol; D016285:Iloprost; C043867:cicaprost